• 대한한방내과학회지
• /
• 제31권2호
• /
• pp.395-400
• /
• 2010

Objective : To observe the effectiveness of Jayeumganghwa-tang on hot flush of a breast cancer patient who takes tamoxifen. Methods : For six weeks a dosage witch contained 13.92g of Jayeumganghwa-tang was administered 3 times (30 mins after meal) per day, for improvement of hot flush. No other therapies like hormone therapy or substituted therapy were done. Results : As a result of 6 weeks of Jayeumganghwa-tang therapy, the patient who suffered hot flush on taking tamoxifen showed improvement on several indices, including frequency, intensity and point of hot flush, Beck Depression Inventory-K (BDI-K) which shows uneasiness and sadness, and also Functional Assessment Cancer Therapy - Breast (FACT-B) which is an index of life quality of breast cancer patients. But no changes on female hormones like follicle-stimulating hormone (FSH) or luteinizing hormone (LH) were observed. Conclusion : This case demonstrates 6 weeks of Jayeumganghwa-tang taking had no effect on female hormones but can reduce the hot flush by tamoxifen. This shows minimum evidence of safety and efficacy of Jayeumganghwa-tang on hot flush of breast cancer patient. However this is a single case study so further case-series research should be compiled.

• Clinical and Experimental Pediatrics
• /
• 제57권9호
• /
• pp.379-383
• /
• 2014

Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve an adult height within the normal target range. GH treatment at a dose of $35-70{\mu}g/kg/day$ should be considered for those with very marked growth retardation, as these patients require rapid catch-up growth. Factors associated with response to GH treatment during the initial 2-3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. Adverse events due to GH treatment are no more common in the SGA population than in other conditions treated with GH. Early surveillance in growth clinics is strongly recommended for children born SGA who have not caught up. Although high dose of up to 0.067 mg/kg/day are relatively safe for short children with growth failure, clinicians need to remain aware of long-term mortality and morbidity after GH treatment.

• Archives of Pharmacal Research
• /
• 제28권5호
• /
• pp.566-572
• /
• 2005

The aim of this study was to determine if the isoflavones from Sophorae fructus (SISO) have potential clinical benefit in hormone replacement therapy (HRT) for the treat ment of menopausal signs, such as the levels of total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and follicle stimulating hormone (FSH). An additional aim was to present the potential antioxidant effect of SISO in a microglial cell line. For the animal model, the ovaries were removed from adult rats and the indicators of menopause were measured at the pre- and post-administration time points. Although no statistically significant correlation was found, SISO tended to decrease the TC level (p=0.15) and the FSH level (p=0.36), but to increase the HDL level (p=0.303).SISO (< 5${\mu}g$/mL) also exerted antioxidant activity on BV-2 microglial cells by inhibiting lipopolysaccharide-induced nitric oxide. This cytoprotective effect was confirmed by trypan blue staining, which was used to test for cellular damage from H$_2O_2$. In conclusion, this study highlights the anti-menopausal and antioxidant effect of SISO in an ovariectomized rat model, as well as in microglial cells, and provides new clinical targets for the screening of phytoestrogens as potential candidates for HRT in menopausal women.

• 수면정신생리
• /
• 제9권2호
• /
• pp.96-99
• /
• 2002

Menopause, the cessation of menstruation caused by the decline in estrogen production, occurs in 95% of women between 40 and 60 years. Sleep disturbance is a frequent complaint during the perimenopause period. In contrast to premenopausla women, menopausal women experience more reduction in the total sleep hours and report more sleep disturbances, such as insomnia, noctiria and sleep disordered breathing. But the prevalence, etiology and treatment of sleep disturbances in menopause are still controversal. So further investigations are required to elucidate the factors that account for the differences in sleep disturbance between premenopausal and postmenopausal women. There are suggestive data that estrogen and progesterone deficiency may increase the susceptibility for sleep disorder in menopause. Furthermore, there are suggestive evidence from observational studies and a limited number of randomized, controlled trials that hormone replacement therapy after menopause improves sleep. However, the clinical relevance of hormone replacement therapy is unproved. So the overall benefit of hormonal replacement in postmenopausal women with sleep related disorders should be individualized to avoid potential side effects. Several studies evaluated the role of melatonin, because this hormone has effects on core body temperature & insomnia. But the exact dosage and the effects of long-term use of melatonin are unclear. So, caution is indicated in melatonin administration.

• Childhood Kidney Diseases
• /
• 제10권2호
• /
• pp.142-151
• /
• 2006

Purpose : Growth retardation is one of the serious problems in children with nephropathy requiring long-term steroid therapy. We observed the efficacy and safety of recombinant human growth hormone(rhGH) on the growth in children with long-term steroid therapy. Methods : We studied 60 children(male 47, female 13) with nephropathy who received rhGH(1 U/kg/week) for more than 0.5 years($1.39{\pm}1.12$). Their mean age was 11.0 years($11.17{\pm}2.62$). They received steroid therapy from January 1987 through July 2005, and the mean duration of steroid therapy was $4.32{\pm}2.97$ years. Among the patients, there were 32 nephrotic syndrome, 9 IgA nephropathy, 4 mesangial proliferative glomerulonephritis, 4 focal segmental glomerulosclerosis, 2 Henoch $Sch\ddot{o}nlein$ nephritis, 2 Alport syndrome and 7 other cases. Data were gathered on the growth parameters, such as growth velocity, height standard deviation score(SDS), IGF-1, IGFBP-3, bone mass density(BMD) and general chemistry changes. Results : Height velocity increased significantly with rhGH therapy from $3.29{\pm}1.95$ to $8.66{\pm}3.75$(cm/yr) and height SDS decreased from $-0.72{\pm}0.93$ to $-1.04{\pm}0.86$ at one year after steroid therapy but increased to $-0.55{\pm}0.96$ at one year after rhGH administration(P<0.05). BMD improved from $0.71{\pm}0.14$ to $0.79{\pm}0.15g/cm^2$(P<0.05). IGF-1 increased from $445.09{\pm}138.01$ to $506.62{\pm}181.31ng/mL$(P<0.05). IGFBP-3 decreased from $4073.75{\pm}700.78$ to $3933.61{\pm}789.25ug/L$ numerically, but there was no statistically significant difference(P=0.533). Conclusion : The administration of rhGH in the short stature patients who received long-term steroid therapy showed improvement in growth parameters such as SDS, growth velocity, and BMD without significant side-effects or changes in the biochemical parameters.

• 수면정신생리
• /
• 제17권1호
• /
• pp.11-15
• /
• 2010

Obstructive sleep apnea is a common sleep disorder that predominantly affects adult men than women. However, the prevalence in women increases with menopause dramatically. Menopause has long been described as a risk factor for obstructive sleep apnea. Recent large well-designed population studies support that menopause increases the risk for sleep-disordered breathing. The mechanism of that hypothesis is not yet clear. But, the decline in progesterone has been thought to influence the development of obstructive sleep apnea because progesterone is a respiratory stimulant and plays a protective role against sleep apnea. Increased visceral obesity and hypertension as major symptoms of metabolic syndrome are also associated with menopause and place women at increased risk for obstructive sleep apnea and other serious health problem. Hormone replacement therapy has been associated with a lower prevalence of sleep apnea. But, relative risk and benefits of hormone replacement therapy compared with other treatment options will require thorough consideration for each individual woman. Finally, attention should be drawn to the need for obstructive sleep apnea evaluation in perimenopausal and postmenopausal women.

• Clinical and Experimental Reproductive Medicine
• /
• 제18권2호
• /
• pp.189-196
• /
• 1991

Long-term administration of luteinizing hormone-releasing hormone(LHRH) agonists, through a process of pituitary desensitization and down-regulation of receptors, inhibits the secretion of gonadotropin and sex-steroids and induces a reversible suppression of gonadal activity. This approach can be used as an effective endocrine therapy for some hormone-dependent tumors. We have used D-Trp6-LHRH, a long acting LHRH agonist, for the treatment of eleven patients with uterine leiomyomas, thereafter myomectomy was performed in seven cases and observed the ultrastructural changes of leiomyoma with an electron microscope. The use of LHRH agonist may be effective in reducing the size of a myoma considerably by primarily inducing medical hypophysectomy and would allow easier surgical removal. Electron microscopic findings of myoma cells after the use of LHRH agonist included the following: loss of cristae and swelling nuclear chromatin, perinuclear vacuolation in cytoplasm. Bone mineral density was slightly decreased, however, the difference was not statistically significant.

• 대한물리치료과학회지
• /
• 제7권2호
• /
• pp.439-457
• /
• 2000

The causes, risk factors and sequelae of mastectomy were studied, and the physical therapy approaches on post-mastectomy was discussed in this study. It was found that the patients taken mastectomy have experienced pins and needles in muscle, weakening of muscle, pains, deterioration of motion in joint region and activities of daily living, psychiatric sequelae, and etc even after the conservertive therapies like the chemical therapy, radiotherapy, immunotherapy, and hormone therapy. However, few study on the physical therapy approaches for patients with breast cancer has been carried in Korea at present. The followings were proposed as the physical therapy approaches. 1. Shoulder joint motion approach to relax the limit of range of motion 2. Control of breathing exercise for dealing with removal of the pectorailis muscle 3. Method to reduce the edema of arms for tackling the cut of lymph node 4. Method to reduce pains, pins and needles 5. Support home exercise program after discharging from hospital, sexual life and pregnancy, and activities of daily living training method.

• Journal of Korean Dental Science
• /
• 제6권1호
• /
• pp.1-3
• /
• 2013

• 보험의학회지
• /
• 제21권
• /
• pp.43-48
• /
• 2002